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Bone creation provides surgical
promise
US researchers from the Massachusetts Institute of
Technology and Vanderbilt University have claimed
to produce predictable quantities of new bone
alongside pre-existing bone using a novel tech-
nique. Such bone production as required, would
mean that patients with degenerative bone dis-
eases or extensive fractures, would avoid the
harvesting of bone from ribs or hips.
Experimentation on rabbits involved pumping
a salt solution into the space between the bone
and periosteum, this was subsequently replaced
with calcium gel, which stimulates bone growth.
Within 6 weeks, the space (or ‘in-vivo bioreactor’)
fills with new bone. Successful duplication of this
technique in a human model and adequacy of the
bone strength is yet to be determined.
Stevens et al. In vivo engineering of organs: the
bone bioreactor. PNAS 2005; 102: 11450e11455.
Hormone injection to suppress
appetite
Researchers at Imperial College, London have dis-
covered Oxyntomodulin, which encourages satiety
signalling to the stomach and is produced post-
prandially by the small intestine. Professor Bloom
demonstrated how artificial administration de-
ceives the brains of overweight subjects. Fourteen
obese and overweight subjects self-administered
Oxyntomodulin before 3 daily meals over a period of
4 weeks, after which they experienced 2.4% body
weight loss. Reductions in the daily-energy intake,
leptin and adipose hormone production have also
been shown.1743-9191/$ - see front matter
doi:10.1016/j.ijsu.2005.08.008Professor Bloom told the IJS: ‘‘An analogue of
the hormone is under development by Thiakis, in
the form of an oral preparation.There will be the
same problems as with the similar peptide hor-
mone, Insulin.’’
Many anti-obesity drugs have a non-specific
mechanism of action, thus generating a large pro-
file of unwanted effects. However, no side effects
or tolerance were identified in this trial. Professor
Bloom commented: ‘‘you have your own injection
every day and it ought to have no side effects.’’
Bloom SR et al. Subcutaneous oxyntomodulin
reduces body weight in overweight and obese
subjects: a double-blind, randomized, controlled
trial. Diabetes 2005; 54: 2390e2395.
Production of worlds first nerve
stem cells
Scientists at the Universities of Edinburgh and Milan
have used human embryonic stem cells to create
pure nerve cells, suitable to treat Parkinson’s and
Alzheimer’s disease and to test the effectiveness
of new drugs. Research led by Professor Austin
Smith, at the University of Edinburgh, estimates
a 2e3-year time span for nerve stem cells to enter
screening systems for new drugs. However, 5e10
years is approximated for nerve cell transplanta-
tion, as it poses more of a challenge.
Hybridisation creates embryonic
stem cells
Fusing adult stem cells with embryonic stem cells
grown in the laboratory will eliminate controversy
surrounding the use of human embryos for research
purposes. Skin cells, from the pelvic area, have
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at Harvard University. This fascinating technique,
essentially ‘resets the genetic clock’ of the adult
skin cells using embryonic cells, but will not be
widely available in research for many years. Such
hybrids exhibit identical differentiation to embry-
onic cells and bear resemblance of their growth
rate and morphology, according to researchers.
Critics fear hybridisation is imperfect and there-
fore not suitable for stem cell treatment. Professor
Ian Wilmut of the University of Edinburgh has
highlighted that the new cells contain double the
number of chromosomes than is normal and there
is currently no suitable method to rectify this.
Cowan et al. Nuclear reprogramming of somatic
cells after fusion with human embryonic stem
cells. Science 2005; 309: 1369e1373.
Dual action of nanocells destroys cancer
Nanocells can infiltrate and attack tumour cells
utilizing a dual mechanism of action, as anti-
angiogenic and chemotherapeutic delivery vessels.
Researchers at Massachusetts Institute of Technol-
ogy demonstrated a unique double chamber tech-
nique to be effective against melanoma and lung
cancer in mice. Eighty percent of mice treated
with nanocells survived greater than 65 days in
comparison to the best current treatment survival
time of 30 days. Healthy cells remain unaltered
and drug delivery issues such as chemotherapy
cycling are avoided, slow release of the chemo-
therapy is restricted to its location.
The nanocell surface escapes host detection
and is based on a double balloon concept. The
outer balloon holds an anti-angiogenic drug, whilst
the inner balloon is a reservoir of chemotherapeutic
agents, released upon disintegration of the mem-
branes. Lead researcher Professor Sasisekharan
told the IJS: ‘‘This model enables us to rationally
and systematically evaluate drug combinations and
loading mechanisms.We want to build on this
concept.’’
Sasisekharan R et al. Temporal targeting of
tumour cells and neovasculature with a nanoscale
delivery system. Nature 2005; 436: 568e572.
Aspirin reduces colorectal cancer risk
The nurses health study of 82,911 women shows
a significant risk reduction for colorectal adeno-
mas with Aspirin use, over a 10-year period. The
doseeresponse relationship was established with
two or more Aspirin or other NSAID’s per week, byresearchers at Massachusetts General Hospital and
Harvard Medical School, USA. The effect may
be attributed to inactivation of the COX-2
enzyme, which is thought to encourage tumour
development.
However, the incidence of major gastrointesti-
nal bleeding also increases with its dose, bleeding
was twice as frequent with the highest doses of
Aspirin. The doses involved are greater than those
used in cardiovascular disease: 14 Aspirin tablets
per week for 10 years, reduces the relative risk by
53%. Further research is required to determine if
the benefits of treatment truly outweigh the risk.
Chan AT et al. Long-term use of aspirin and
nonsteroidal anti-inflammatory drugs and risk of
colorectal cancer. JAMA 2005; 294: 914e923.
Discovery of gene as breast cancer
vaccine target
The TPRS-1 gene, regulating normal embryonic
development, is found in all forms of breast
cancer. Normally produced in healthy tissue, it
is over-expressed in cancerous cells, according
to research by Professor Radvanyi, at the M.D.
Anderson Cancer Centre, USA. This cancer specific
protein can be used as the molecular target for the
immune system to attack tumour cells and may
spearhead vaccine formation. Radvanyi has hy-
pothesised that the protein may regulate cell
growth and perhaps oestrogen recognition. It is
thought to be involved in the earliest stages of
breast cancer. Experimentation has shown T-cells
detecting TPRS-1, will attack breast cancer cells
containing this protein. The aim is to correlate
TPRS-1 levels with breast cancer markers and to
identify the precise protein target within the cells
to aid drug development.
Radvanyi L et al. The gene associated with
trichorhinophalangeal syndrome in humans is over-
expressed in breast cancer. PNAS 2005; 102:
11005e11010.
Herceptin fast tracked by british health
secretary
Successful preliminary tests of the breast cancer
drug Herceptin, prompted the British Health sec-
retary, Ms. Patricia Hewitt, to order its rapid
assessment. Currently, it is solely licensed for the
treatment of advanced HER-2 positive breast
cancer. Intervention has arisen following concerns
that patients who may potentially benefit from
178 O. Shafiqsuch treatment are being denied; furthermore
delays in access were identified in a report by
the charity CancerBACUP.
Assessment of Herceptin by the National In-
stitute for Clinical Excellence (NICE) will deter-
mine the feasibility of extending its use. Insurance
company BUPA has stated that it will fund Hercep-
tin treatment for early stage breast cancer pa-
tients, subsequent to licensing approval expected
by November 2006.
Herceptin is approved treatment for recurrent
or metastatic breast cancers in the USA. Two
National Cancer Institute randomised trials were
conducted, of 3000 women with surgically re-
moved HER-2 positive tumours, but no spread
beyond neighbouring lymph nodes or recurrence.
A 52 percent decrease in recurrence in women
receiving Herceptin alongside standard chemo-
therapy was achieved.
Hudis C et al. Testing chemotherapy for breast
cancer: timing is everything. J Clin Oncol 2005; 23:
5434e5436.
Global vision of academic medicine
in 2025
The International Campaign to Revitalise Academic
Medicine (ICRAM) proposed 5 scenarios for the
future of academic medicine, based over 20 years.
Growing concerns that academic medicine faces
crisis in the future prompted this global initiative.
Significant ‘future change drivers,’ including newtechnology, sophisticated consumerism and pres-
ent instability, forms the basis of the constructed
scenarios. ICRAM aims to achieve broader thinking
and envisages the adopted scheme in 2025 to
incorporate elements from each of the 5 diverse
models:
1. ‘‘Academic Inc:’’ private sector domination.
2. ‘‘Reformation:’’ fusion of research and educa-
tion with health care.
3. ‘‘The Public Eye:’’ powerful interaction of the
media and extreme consumerism.
4. ‘‘Global Academic Partnership:’’ strives for
global health equity.
5. ‘‘Fully Engaged system:’’ robust relationships
with stakeholders is enforced.
However, most influences upon academic med-
icine, namely social, economic and political fac-
tors, remain outside the boundaries of those
involved.
The full report ‘‘The Future of Academic Med-
icine: 5 scenarios to 2025’’ is published by the
Millbank Memorial Fund and is available from:
http://www.milbank.org/reports/0507FiveFutures/
0507FiveFutures.html.
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